756813-88-4 Usage
General Description
Methyl 2-(4-amino-3-iodophenyl)-2-methylpropanoate is a chemical compound with the molecular formula C11H14INO2. It is a derivative of 2-amino-3-iodobenzoic acid, and contains a methyl ester and a 2-methylpropanoate moiety. Methyl 2-(4-amino-3-iodophenyl)-2-methylpropanoate is commonly used in organic synthesis and pharmaceutical research as a building block for the preparation of various pharmaceuticals and bioactive molecules. It is also used as a reagent in chemical reactions and as a precursor in the synthesis of complex organic compounds. Methyl 2-(4-amino-3-iodophenyl)-2-methylpropanoate is considered to be a potentially hazardous chemical and must be handled and stored according to proper safety guidelines and regulations.
Check Digit Verification of cas no
The CAS Registry Mumber 756813-88-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,5,6,8,1 and 3 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 756813-88:
(8*7)+(7*5)+(6*6)+(5*8)+(4*1)+(3*3)+(2*8)+(1*8)=204
204 % 10 = 4
So 756813-88-4 is a valid CAS Registry Number.
756813-88-4Relevant articles and documents
Enantiospecific and regioselective opening of 2-alkyl nosylaziridines by indoles mediated by boron trifluoride. Application to a practical synthesis of a GnRH antagonist
Farr, Roger N.,Alabaster, Ramon J.,Chung, John Y.L.,Craig, Bridgette,Edwards, John S.,Gibson, Andrew W.,Ho, Guo-Jie,Humphrey, Guy R.,Johnson, Simon A.,Grabowski
, p. 3503 - 3515 (2003)
An efficient, high yield process for the synthesis of a GnRH antagonist has been developed. We have demonstrated that under boron trifluoride mediation, nosyl aziridines will react with 2-arylindole derivatives to afford β-substituted tryptamines in an enantiospecific process with remarkably high regioselectivity. The scope of the reaction was explored with several 2-substituted nosyl aziridines. The key reaction was developed expressly for the GnRH antagonist program and has been demonstrated on 40 kilogram scale.
